Arylsulfonamidothiazoles as a New Class of Potential Antidiabetic Drugs. Discovery of Potent and Selective Inhibitors of the 11β-Hydroxysteroid Dehydrogenase Type 1
Tjeerd Barf(Pearson (United States)), Lars Abrahmsén(Swedish Orphan Biovitrum (Sweden)), Vivienne Larwood(BioClinica (United States)), Birgitta Öhman(Swedish Orphan Biovitrum (Sweden)), Pēteris Alberts(Maxygen (United States)), Naimie H. M. Edling(Swedish Orphan Biovitrum (Sweden)), Rikard Emond(BioClinica (United States)), Erifili Mosialou(BioClinica (United States)), Kent Axelsson(BioClinica (United States)), Yuko Rönquist-Nii(Swedish Orphan Biovitrum (Sweden)), Charlotta Häggström(BioClinica (United States)), Alf S. Nygren(BioClinica (United States)), Lars O. M. Engblom(Swedish Orphan Biovitrum (Sweden)), Jerk Vallgårda(BioClinica (United States)), Rolf Olsson(BioClinica (United States)), Guido Kurz(BioClinica (United States))
Cited by 211
Related Papers
Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile
|Journal of Pharmacology and Experimental Therapeutics|2017|366
Selective Inhibition of 11β-Hydroxysteroid Dehydrogenase Type 1 Improves Hepatic Insulin Sensitivity in Hyperglycemic Mice Strains
|Endocrinology|2003|263
Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice
|Diabetologia|2002|259
The advent of oncolytic virotherapy in oncology: The Rigvir® story
|European Journal of Pharmacology|2018|179